Building a Culture of Constructive Dissent in the Boardroom
Most catastrophic board decisions in biopharma do not happen because no director saw the problem. They happen because the directors who saw the problem did not raise it, or raised it once and did not press, or were uncertain enough about their own judgment that they let the room's apparent consensus override their private doubt.
This is not a failure of individual courage. It is a failure of board culture. The boards that consistently make good decisions are not the ones populated by unusually brave directors. They are the ones in which raising a dissenting view is treated as a normal, expected, and welcomed part of the work — and in which the social and structural conditions for honest disagreement have been deliberately built rather than left to chance.
Building that culture is one of the most consequential governance investments a board can make. It is also one of the least discussed, because it does not appear in committee charters, bylaws, or governance policies. It lives in the texture of how board meetings are run, in the norms that develop over time, in the small choices a chair makes in any given meeting that either invite dissent or quietly discourage it.
This article is about what those choices look like, why they matter so much in clinical-stage biopharma, and how a board chair and its directors can build the culture in practice.
Why Groupthink Is Especially Dangerous in Biopharma
Every board is susceptible to groupthink. The dynamics that produce it — social pressure to agree, deference to authority, the desire to maintain harmony, the implicit cost of being the one who slows things down — operate across every industry and every type of organization. What makes biopharma boards especially exposed is the combination of three factors.
The first is the structure of the decisions. Most of the consequential decisions a clinical-stage biopharma board makes are non-recurring. The board will decide once whether to advance a candidate into Phase II, once whether to enter into a particular partnership, once whether to file for accelerated approval, once whether to pursue a particular financing structure. These are not decisions where the board accumulates a track record of feedback that allows it to calibrate its judgment over time. The decision is made, the consequences unfold over years, and by the time the board can assess whether the decision was right, the relevant counterfactuals are no longer available.
This structure favors groupthink in a specific way. When a board is making a one-time decision under uncertainty, the social cost of disagreement is high and the personal benefit is low. A director who raises a concern that turns out to have been valid receives little vindication, because the alternative was never tested. A director who raises a concern that turns out to have been wrong absorbs the social cost of having been the obstacle. The asymmetry produces a quiet, steady pressure toward agreement.
The second factor is the technical complexity of the substantive material. Biopharma board decisions often involve scientific, clinical, and regulatory questions that no single director fully understands at the level of detail required to challenge the recommendation with confidence. The directors who do have the deepest expertise — often a single scientific director, or the CEO, or an external consultant — carry disproportionate weight in the room. Other directors, conscious of their relative knowledge gap, often defer rather than press. The deference is reasonable in any individual instance and corrosive in aggregate.
The third factor is the time compression of clinical-stage decisions. Boards are frequently asked to make consequential decisions under timelines driven by external events — a financing window, a regulatory deadline, an enrollment milestone, a partner's negotiating posture. The compressed timeline reduces the space for genuine deliberation and amplifies the pressure to converge on a decision. Directors who would otherwise raise concerns find themselves making private peace with the apparent consensus because the time for working through the disagreement was not made available.
Together, these three factors produce a governance environment in which honest dissent is structurally disadvantaged. The boards that overcome this are the ones that deliberately build culture and structure against the prevailing pressure.
What Constructive Dissent Actually Looks Like
It is worth being precise about what is being advocated for, because the word "dissent" can suggest something more confrontational than what good governance actually requires.
Constructive dissent is not the same as obstruction. It is not adversarial. It is not driven by the personality preferences of contrarian directors. It is, in practical terms, the ordinary practice of asking the questions that need to be asked before a decision is finalized, surfacing the considerations that the dominant narrative has not addressed, and ensuring that the board's eventual decision reflects genuine engagement with the relevant uncertainties rather than premature convergence.
In a healthy board culture, constructive dissent looks like a director saying: "I'd like to understand why we're not considering option C." It looks like a director saying: "The data we just heard about supports the recommendation, but the previous data point cut the other way — how are we weighing them?" It looks like a director saying: "Before we vote, I want to articulate the case against this, so we can be sure we've considered it." It looks like a director asking the CEO, in front of the rest of the board, what would have to be true for the recommendation to be wrong.
None of these interventions are obstructionist. None of them require the dissenting director to be ultimately correct. They simply ensure that the board's decision is the product of deliberate consideration rather than the path of least resistance.
The boards that have built this culture treat these interventions as ordinary contributions to the work. The boards that have not built this culture treat them as friction — and the directors who learn this lesson stop making the interventions, regardless of whether they continue to have the underlying concerns.
The Role of the Chair
The single largest determinant of whether a board develops a culture of constructive dissent is the behavior of the chair. The chair sets the tone of every meeting through choices that are often invisible to the directors themselves: how the agenda is sequenced, how time is allocated, how the chair responds to the first dissenting comment of any given meeting, how the chair handles the transition from discussion to decision, and whether the chair signals, in dozens of small ways, that disagreement is welcomed or that it is merely tolerated.
A chair who wants to build a culture of constructive dissent does several specific things, consistently, over a long period of time.
They build in time for genuine discussion before votes. They resist the temptation to compress agendas to the point where the most important items receive the least time. They open the floor explicitly for concerns before any decision is finalized, in language that invites contribution rather than language that merely permits it. The difference between "Any concerns?" (which signals that concerns are an exception to expected agreement) and "Before we decide, what are we missing?" (which signals that something is always missing and the question is what) is small in any one meeting and large over the course of a year.
They normalize their own dissent. A chair who occasionally articulates a counter-position before a vote — even one they ultimately do not endorse — demonstrates to other directors that doing so is part of the work. A chair who never visibly disagrees with the management recommendation, even on close decisions, signals that disagreement is not normal.
They protect dissenting directors from social consequences. When a director raises a concern that slows the discussion, the chair's response in the next few seconds is consequential. A chair who thanks the director, restates the concern accurately, and invites further engagement is building culture. A chair who waves the concern aside, signals impatience, or returns the discussion to the original track without genuine engagement is doing the opposite. Other directors are watching, and they are calibrating how much social cost is associated with raising similar concerns themselves.
They hold executive sessions routinely. The executive session — board time without management present — is the single most important structural condition for constructive dissent on most boards. It is where directors can speak candidly about concerns that they may not yet want to raise in front of the CEO, where the chair can probe for unspoken reservations, and where the board can develop a collective view that is not filtered through management's framing. Boards that hold executive sessions only when something has gone wrong have already missed the value. Boards that hold them after every regular meeting, as a matter of routine, have built one of the most important governance structures available to them.
They model intellectual humility. A chair who occasionally says "I'm not sure" or "I want to think about that further" or "I was wrong about something last meeting" creates space for other directors to do the same. A chair who always projects certainty produces a board in which everyone else feels the need to project certainty as well, which is corrosive to the kind of honest engagement that good decisions require.
Structural Supports for Dissent
Culture matters most, but structure matters too. There are specific governance practices that make constructive dissent easier and others that make it harder, and boards that take this question seriously can deliberately adopt the practices that support what they are trying to build.
A few are worth naming.
The first is the use of pre-read materials and adequate time to review them. When directors arrive at a meeting having had genuine time to engage with the substantive material in advance, they bring informed questions and considered concerns. When directors arrive at a meeting with materials they received the night before, they default to the recommendation in front of them because they have not had time to develop an independent view. Tight pre-read timelines are one of the most reliable structural producers of groupthink in biopharma board work, and many of them could be avoided with better meeting cadence.
The second is the deliberate use of devil's advocate roles. On consequential decisions, the chair can ask a specific director — rotating across meetings — to develop and present the strongest case against the proposed recommendation, regardless of the director's own view. This converts dissent from a social risk into an assigned task, and it ensures that the case against any decision has been articulated as fully as the case for it. The boards that use this practice well find that it produces better decisions even when the original recommendation is ultimately approved, because the deliberation has been genuine rather than perfunctory.
The third is the structured separation of options generation from options selection. Boards that move directly from "here is the management recommendation" to "let's discuss whether to approve it" are working in a frame that disadvantages alternatives. Boards that begin with "what are the realistic options here" before management's recommendation is presented, and only then move to evaluation, work in a frame that produces broader deliberation. This is a small change in agenda structure with significant effects on the quality of discussion.
The fourth is the practice of going around the table on consequential decisions, with each director articulating their view briefly before the vote. This practice forces directors who might otherwise stay silent to take a position, and it surfaces disagreements that might otherwise remain implicit. It also has the effect of distributing the social burden of dissent across the room rather than concentrating it on whichever director happens to speak first.
None of these structural practices substitute for healthy culture. But they support it, and a board that has both — culture and structure — produces qualitatively different decisions than a board that has neither.
The CEO's Role
A board culture of constructive dissent is not built only by the board. The CEO's behavior matters, often decisively. A CEO who responds to board challenge with defensiveness, who treats hard questions as evidence of disloyalty, or who manages the board's information flow to suppress concerns is making the chair's job — and the board's job — significantly harder than it needs to be.
The most effective CEOs treat the board's challenge function as part of what they pay for. They actively invite hard questions. They present recommendations with the genuine alternatives, not just the preferred path. They are willing to articulate their own uncertainty rather than projecting false confidence. They make space for the chair to probe, and for individual directors to disagree, without taking either as an attack.
This posture is not natural for many CEOs, particularly founder-CEOs who built the company on the strength of their own conviction. But it is learnable, and the CEOs who learn it tend to have better board relationships, better board engagement, and ultimately better decisions than the CEOs who do not. A board that has the right culture but a CEO who actively undermines it will struggle. A board and a CEO that have built this culture together produces the kind of governance environment that distinguishes the strongest biopharma companies.
The chair has a role here as well. When the chair sees the CEO defaulting to defensive postures or managing information flow in ways that suppress concerns, the chair's private conversation with the CEO matters. This is one of the most important informal governance functions in any biopharma company, and it is handled almost entirely off the record, in conversations that never appear in the minutes.
Why This Is Worth the Investment
Building a culture of constructive dissent takes time, attention, and consistent effort over a period of years. It is not the kind of work that produces visible results in any individual meeting. It is the kind of work whose value shows up in the decisions a board avoids making badly, in the catastrophes it does not produce, in the trajectory the company takes when a critical choice is made well rather than poorly.
In clinical-stage biopharma, where the consequences of board decisions are absorbed by shareholders, by employees, and ultimately by patients enrolled in trials, the case for making this investment is unusually strong. The boards that build this culture deliberately are not perfect, and they do not avoid every mistake. But they avoid the specific category of mistakes that come from premature convergence, suppressed concerns, and the social pressure to agree — and that category, in biopharma, contains many of the most costly failures the industry has produced.
The investment is real. The return, when it comes, is structural — and worth the work that produces it.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.